INR 1448.25
(0.35%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -14.67 Billion INR | 22.96% |
2022 | -19.04 Billion INR | -556.52% |
2021 | -2.9 Billion INR | 40.41% |
2020 | -4.86 Billion INR | -197.78% |
2019 | -1.63 Billion INR | 28.85% |
2018 | -2.29 Billion INR | 37.17% |
2017 | -3.65 Billion INR | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -25.25 Billion INR | 0.0% |
2023 Q2 | -1.23 Billion INR | 0.0% |
2023 FY | -14.67 Billion INR | 22.96% |
2023 Q4 | -14.67 Billion INR | 0.0% |
2023 Q3 | - INR | 100.0% |
2023 Q1 | - INR | 100.0% |
2022 Q1 | - INR | 100.0% |
2022 Q4 | -19.04 Billion INR | 0.0% |
2022 Q3 | - INR | 100.0% |
2022 FY | -19.04 Billion INR | -556.52% |
2022 Q2 | -5.29 Billion INR | 0.0% |
2021 Q3 | - INR | 100.0% |
2021 Q2 | -2.66 Billion INR | 0.0% |
2021 FY | -2.9 Billion INR | 40.41% |
2021 Q1 | - INR | 100.0% |
2021 Q4 | -2.9 Billion INR | 0.0% |
2020 Q4 | -4.86 Billion INR | 0.0% |
2020 Q1 | -3.75 Billion INR | -129.86% |
2020 FY | -4.86 Billion INR | -197.78% |
2019 FY | -1.63 Billion INR | 28.85% |
2019 Q4 | -1.63 Billion INR | 0.0% |
2018 FY | -2.29 Billion INR | 37.17% |
2017 FY | -3.65 Billion INR | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Abbott India Limited | -20.51 Billion INR | 28.47% |
Cipla Limited | -3.15 Billion INR | -364.972% |
GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | -2076.597% |
Kopran Limited | 850.3 Million INR | 1825.582% |
Marksans Pharma Limited | -4.29 Billion INR | -241.609% |
NGL Fine-Chem Limited | 307.22 Million INR | 4875.883% |
Pfizer Limited | -19.52 Billion INR | 24.839% |
Sanofi India Limited | -3.87 Billion INR | -278.649% |
SMS Pharmaceuticals Limited | 2.44 Billion INR | 699.942% |